Citing downstream costs and potential consequences for patients, lobbyists for opioid manufacturers and pharmacies pushed back Wednesday against a bill that would charge major drugmakers for pills they sell in Delaware.

Opponents of the measure told members of a Senate committee that pharmacies and consumers would end up paying the cost of the proposal, which aims to create a two-tier “impact fee” on pharmaceutical firms that produce the highest-strength and most widely distributed opioid products available for sale in the state.